Phasebio Pharmaceuticals (PHAS) Return on Equity ROE from the second quarter 2022 to second quarter 2021 and annually, average high and low, overall ranking from Jun 30 2022 to Jun 30 2021 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Phasebio Pharmaceuticals Inc.  (NASDAQ: PHAS)

Phasebio Pharmaceuticals's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Phasebio Pharmaceuticals in the second quarter 2022?
Due to the lack of equity, it was not possible to calculate Phasebio Pharmaceuticals Inc.'s return on equity (ROE) in its second quarter 2022

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2022)
II. Quarter		 (Mar 31 2022)
I. Quarter		 (Dec 31 2021)
IV. Quarter		 (Sep 30 2021)
III. Quarter		 (Jun 30 2021)
II. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -103 -115 -131 -118 -112
Return On Equity (TTM) - - - - -
PHAS's Total Ranking # # # # #
Equity (TTM) in Millions -117 -102 -93 -50 -19
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to PHAS Management Effectiveness >> PHAS's 5 Years Annual ROE >> Compare PHAS ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





PHAS Annual Return On Equity (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2018)
2018
Total Equity in Millions -93 -25 60 51 0
Y / Y Equity Change - - 17.77 % - -
Net Income in Millions -131 -99 -39 -24 0
Y / Y Net Income Change - - - - -
Return On Equity - - -65.44 % -46.82 % -

Back to PHAS Management Effectiveness >> PHAS's 5 Years Annual ROE >> Compare PHAS ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
PHAS's' Return on Equity at Yahoo Finance
PHAS's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for PHAS's Competitors
Subscribers only: Roe for Phasebio Pharmaceuticals's Suppliers
Subscribers only: Return On Equity for PHAS's Customers




Companies with similar Return On Equity at Jun 30 2022, within Healthcare Sector ROE
Waters Corporation  196.42 %
Molecular Templates Inc   164.06 %
Amgen Inc   144.12 %
Halozyme Therapeutics Inc   141.91 %
Effector Therapeutics Inc   121.96 %
Aptevo Therapeutics Inc   109.76 %
Avid Bioservices Inc   106.62 %
Idexx Laboratories Inc  104.46 %
Davita Inc   104.44 %
Moderna Inc   94.76 %
Dynavax Technologies Corporation  93.16 %
Journey Medical Corp  85.14 %
Cartesian Therapeutics Inc   85.07 %
Abbvie Inc   84.29 %
Biomx Inc  83.21 %
Vicarious Surgical Inc  82.59 %
Maravai Lifesciences Holdings Inc   79.73 %
Sensus Healthcare Inc   74.85 %
Tenet Healthcare Corp  74.11 %
Vir Biotechnology Inc   68.86 %
Biofrontera Inc   65.87 %
Vivos Therapeutics Inc   65.69 %
Eli Lilly And Company  64.62 %
Iteos Therapeutics Inc   60.26 %
Oncotelic Therapeutics Inc   59.84 %
Vyne Therapeutics Inc   54.91 %
Siga Technologies Inc  48.79 %
REST EZ Inc.  48.50 %
Glucotrack Inc   47.72 %
Nrc Health  45.39 %

Date modified: 2026-09-26T07:35:42+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.